The medical community has always assumed that patients with cancer would be strictly adherent to their prescribed regimens due to the severity of the disease but that hasn’t been the case. In studies of women with early breast cancer prescribed tamoxifen, the non-adherence rate has been nearly 50% by the end of the 5-year prescribed term. URA Rx Group understands that The reasons for non-adherence are multifactorial and include poor understanding of the disease and/or treatment, complexity of the regimen, treatment-related side effects, poor follow-up with the healthcare provider, financial concerns and loss of trust in the efficacy of the treatment. Oncology nurses provide the bulk of patient education regarding medications and side effects, but face-to-face time in busy clinics and offices is limited by the sheer numbers of patients and a shortage of oncology certified nurses. URA Rx has found that although non-adherence is more prevalent in oral regimens than I.V., non-adherence to I.V. regimens is also a problem. For patients on long-term I.V. regimens, there is an increased risk of missed appointments or being lost to follow-up until the disease progresses and the patient returns to clinic because of increased symptoms. This is a common problem with I.V. bisphosphonates. At URA Rx, we have found that patients respond well to outside support that reinforces the office nurse’s education, helps patients track and resolve side effects, and keeps the patient focused on the reasons for maintaining adherence to therapy and the ultimate goal, which is to achieve the best possible outcome for management of their cancer.